ZBTB7A and Schnyder corneal dystrophy: Other studies have used CRISPR–Cas9 to edit γ‐globin repressor ZBTB7A/LRF binding sites to simulate HPFH mutations, restore HbF synthesis, and correct SCD phenotypes, suggesting that ZBTB7A/LRF binding sites are effective targets for SCD genome editing therapy.250